Immunofluorescent analysis of (4% PFA) fixed HepG2 cells using CL488-66037 (Green, ATP5A1 antibody) at dilution of 1:100 and CL594-66187 (Red, Cytokeratin 18 antibody) at dilution of 1:100.
1X10^6 HeLa cells were intracellularly stained with 0.20 ug/test CoraLite®488-conjugated Anti-Human ATP5A1 (CL488-66037, Clone:1B10H3) (red) or 0.20 ug control antibody (blue). Fixed with90% MeOH.
Various lysates were subjected to SDS PAGE followed by western blot with CL488-66009 (Beta Actin antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours.
Immunofluorescent analysis of (-20°C Ethanol) fixed HepG2 cells using CL488-66009 (beta Actin antibody) at dilution of 1:100.
1X10^6 HeLa cells were stained with 0.20ug beta Actin antibody (CL488-66009, red) and control antibody (blue). Fixed with 90% MeOH.
Immunofluorescent analysis of (-20°C Ethanol) fixed HepG2 cells using CL488-60187 (Cytokeratin 19 antibody) at dilution of 1:50.
1X10^6 HeLa cells were surface stained with 0.5 ug CoraLite®488-conjugated Anti-Human Cytokeratin 19 (CL488-60187, Clone:3G1E4) (green), and 0.5 ug Control Antibody. Samples were fixed with 90% MeOH.
Immunofluorescent analysis of (-20°C Ethanol) fixed HeLa cells using CL488-66373 (G6PD antibody) at dilution of 1:50.
1X10^6 HeLa cells were surface stained with 0.50 ug/test CoraLite®488-conjugated Anti-Human G6PD (CL488-66373, Clone:2A7B12) (red) or 0.50 ug control antibody (blue). Fixed with90% MeOH.
